BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) (“Rich”), with the advice and guidance of Theradex Systems, Inc., Rich’s Contract Research Organization, has submitted additional information to the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) to conduct clinical trials for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS). This is the third submission (#0003) to the FDA by Rich to continue the efforts to move forward with the next phase of clinical studies using RP-323 to treat AML and MDS patients.
“We believe this submission should satisfy the FDA’s requirements and we look forward to focusing our efforts in expanding our trials to new clinical sites in the USA and overseas,” said Ben Chang, Chief Executive Officer.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML), Myelodysplastic Syndromes (MDS), and Hodgkin’s Lymphoma. Rich Pharmaceuticals’ goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals’ primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.
Notice Regarding Forward-Looking Statements:
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Contact:
Ben Chang, CEO
9595 Wilshire Blvd., Suite 900
Beverly Hills, CA 90212
info@richpharmaceuticals.com
Logo - http://photos.prnewswire.com/prnh/20151006/274760LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-announces-additional-submission-to-the-us-food-and-drug-administration-fda-300183133.html
SOURCE Rich Pharmaceuticals, Inc.
